13D Filing: Alafi Capital Co LLC and Intra-Cellular Therapies Inc. (ITCI)

Page 3 of 12

Page 3 of 12 – SEC Filing


SCHEDULE 13D
CUSIP No. 46116X 101 Page
3
of 13 Pages
  1 

Name of
reporting person

Christopher Alafi, Ph.D.

  2

Check the appropriate box if a member
of a group

(a)  ☐        (b)  ☒ (joint filers)

  3

SEC use only

  4

Source of funds

    OO/PF

  5

Check if disclosure of legal
proceedings is required pursuant to Item 2(d) or 2(e)    ☐

  6

Citizenship or place of
organization

    United States

Number of

shares

beneficially

owned by

each

reporting

person

with

  7 

Sole voting power

    1,327,594
shares2

  8

Shared voting power

    3,953,270
shares3

  9

Sole dispositive power

    1,327,594
shares4

10

Shared dispositive power

    3,953,270
shares5

11

Aggregate amount beneficially owned by each reporting person

    5,280,864 shares6

12

Check if the aggregate amount in Row
(11) excludes certain shares    ☐

13

Percent of class represented by amount
in Row (11)

    9.7%7

14

Type of reporting person

    IN

2 Consists of 503,753 shares held by a trust for the benefit of members of the Alafi family, 734,466 shares held by Dr. Alafi individually and options to purchase 89,375 shares exercisable within 60 days of October 5,
2017 held by Dr. Alafi. The Reporting Person has full voting and investment power with respect to the shares held by the trust. Does not include 503,776 shares held by two other trusts for the benefit of members of the Alafi family for which the
Reporting Person does not have voting or investment control.
3 Consists of 3,953,270 shares owned by Alafi Capital Company, LLC (Alafi Capital). The Reporting Person is a managing partner of Alafi Capital and shares voting and investment power with respect to the shares
that Alafi Capital holds. The Reporting Person disclaims beneficial ownership of shares held by Alafi Capital except as to the extent of his pecuniary interest in such shares.
4 See Footnote 2.
5 See Footnote 3.
6 See Footnotes 2 and 3.
7 See Footnote 1.

Follow Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

Page 3 of 12